High 4-gene inflammatory score	Mesothelioma	High 4-gene inflammatory score	Mesothelioma	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B
CD8 expression	Prostate Cancer	CD8 expression	Prostate Cancer	atezolizumab + enzalutamide Sensitive: B - Late Trials atezolizumab + enzalutamide Sensitive : B	atezolizumab + enzalutamide Sensitive: B - Late Trials atezolizumab + enzalutamide Sensitive : B
CD8 expression	Melanoma	CD8 expression	Melanoma	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2	pembrolizumab Sensitive: C2 – Inclusion Criteria pembrolizumab Sensitive : C2
CD8 overexpression	Non Small Cell Lung Cancer	CD8 overexpression	Non Small Cell Lung Cancer	PF-06801591 Sensitive: C3 – Early Trials PF-06801591 Sensitive : C3	PF-06801591 Sensitive: C3 – Early Trials PF-06801591 Sensitive : C3
CD8 overexpression	Melanoma	CD8 overexpression	Melanoma	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3	ipilimumab Sensitive: C3 – Early Trials ipilimumab Sensitive : C3
PD-L1 overexpression + CD8 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression + CD8 overexpression	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
PD-1 overexpression + CD8 positive	Non Small Cell Lung Cancer	PD-1 overexpression + CD8 positive	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3
CD8-H	Triple Negative Breast Cancer	CD8-H	Triple Negative Breast Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
CD8 expression	Urothelial Cancer	CD8 expression	Urothelial Cancer	PF-06801591 Sensitive: C3 – Early Trials PF-06801591 Sensitive : C3	PF-06801591 Sensitive: C3 – Early Trials PF-06801591 Sensitive : C3
TCF7 overexpression + CD8 overexpression	Melanoma	TCF7 overexpression + CD8 overexpression	Melanoma	PD-L1 inhibitor + CTLA4 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor + CTLA4 inhibitor Sensitive : C3	PD-L1 inhibitor + CTLA4 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor + CTLA4 inhibitor Sensitive : C3
CD8 overexpression	Non Small Cell Lung Cancer	CD8 overexpression	Non Small Cell Lung Cancer	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3	pembrolizumab Sensitive: C3 – Early Trials pembrolizumab Sensitive : C3
CD8 positive	Non Small Cell Lung Cancer	CD8 positive	Non Small Cell Lung Cancer	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3	PD-L1 inhibitor Sensitive: C3 – Early Trials PD-L1 inhibitor Sensitive : C3

CD8 (cluster of differentiation 8)

Associations(42)

Associations
(42)